Skip to Main Content

Paper Details

Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy.
Blood Adv
8
2022
CAR, CD19, malignant neoplasms
Author NameAffiliation
Seth M SteinbergNational Cancer Institute, National Institutes of Health
Seth M SteinbergNational Cancer Institute, National Institutes of Health
Stephan A GruppChildren's Hospital of Philadelphia
Adam J LambleUniversity of Washington, Seattle Children's Hospital
  • 1 - 4

Datasets

Release 1.2